Clinical Research Institute, Duke University Medical Center, 2400 Pratt St., Durham, NC 27705, USA.
Circulation. 2013 Aug 27;128(9):954-61. doi: 10.1161/CIRCULATIONAHA.112.000488. Epub 2013 Jul 17.
Recoarctation after the Norwood procedure increases risk for mortality. The Single Ventricle Reconstruction (SVR) trial randomized subjects with a single right ventricle undergoing a Norwood procedure to a modified Blalock-Taussig shunt or a right ventricle-pulmonary artery shunt. We sought to determine the incidence of recoarctation, risk factors, and outcomes in the SVR trial.
Recoarctation was defined by intervention, either catheter based or surgical. Univariate analysis and multivariable Cox proportional hazard models were performed with adjustment for center. Of the 549 SVR subjects, 97 (18%) underwent 131 interventions (92 balloon aortoplasty, 39 surgical) for recoarctation at a median age of 4.9 months (range, 1.1-10.5 months). Intervention typically occurred at pre-stage II catheterization (n=71, 54%) or at stage II surgery (n=38, 29%). In multivariable analysis, recoarctation was associated with the shunt type in place at the end of the Norwood procedure (hazard ratio, 2.0 for right ventricle-pulmonary artery shunt versus modified Blalock-Taussig shunt; P=0.02), and Norwood discharge peak echo-Doppler arch gradient (hazard ratio, 1.07 per 1 mm Hg; P<0.01). Subjects with recoarctation demonstrated comorbidities at pre-stage II evaluation, including higher pulmonary arterial pressures (15.4±3.0 versus 14.5±3.5 mm Hg; P=0.05), higher pulmonary vascular resistance (2.6±1.6 versus 2.0±1.0 Wood units·m(2); P=0.04), and increased echocardiographic volumes (end-diastolic volume, 126±39 versus 112±33 mL/BSA(1.3), where BSA is body surface area; P=0.02). There was no difference in 12-month postrandomization transplantation-free survival between those with and without recoarctation (P=0.14).
Recoarctation is common after Norwood and contributes to pre-stage II comorbidities. Although with intervention there is no associated increase in 1-year transplantation/mortality, further evaluation is warranted to evaluate the effects of associated morbidities.
在 Norwood 手术后再狭窄会增加死亡率。Single Ventricle Reconstruction(SVR)试验将接受 Norwood 手术的单心室患者随机分为改良 Blalock-Taussig 分流术或右心室-肺动脉分流术。我们旨在确定 SVR 试验中再狭窄的发生率、危险因素和结果。
再狭窄的定义为介入治疗,包括导管介入或手术。采用单变量分析和多变量 Cox 比例风险模型进行分析,并对中心进行调整。在 549 名 SVR 患者中,97 名(18%)接受了 131 次干预(92 次球囊主动脉成形术,39 次手术)治疗再狭窄,中位年龄为 4.9 个月(范围为 1.1-10.5 个月)。干预通常发生在二期前导管检查时(n=71,54%)或二期手术时(n=38,29%)。多变量分析显示,再狭窄与 Norwood 手术后分流类型有关(右心室-肺动脉分流术的风险比为 2.0,与改良 Blalock-Taussig 分流术相比;P=0.02),以及 Norwood 出院时超声心动图升主动脉弓梯度(风险比,每增加 1mmHg 为 1.07;P<0.01)。再狭窄患者在二期前评估时存在合并症,包括肺动脉压较高(15.4±3.0 与 14.5±3.5mmHg;P=0.05)、肺血管阻力较高(2.6±1.6 与 2.0±1.0Wood 单位·m2;P=0.04)和超声心动图容量增加(舒张末期容积,126±39 与 112±33mL/BSA(1.3),BSA 为体表面积;P=0.02)。再狭窄组和无再狭窄组 12 个月后随机无移植生存率无差异(P=0.14)。
Norwood 手术后再狭窄很常见,并导致二期前合并症。尽管通过介入治疗,1 年移植/死亡率没有增加,但需要进一步评估以评估相关合并症的影响。